Weil is advising Eli Lilly and Company in its agreement to acquire Loxo Oncology for approximately $8 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. The transaction is expected to close by the end of the first quarter of 2019 and is subject to customary closing conditions.
The Weil team advising Eli Lilly is led by Mergers & Acquisitions partners Raymond Gietz and Matthew Gilroy and includes Mergers & Acquisitions associates Aileen Kim, Stephen Liebscher, Mario Carroll and Bilal Chaudhry (Not Yet Admitted in New York); Technology & IP Transactions partner Jeffrey Osterman; Tax partner Helyn Goldstein; Executive Compensation & Benefits partner Amy Rubin; Patent Litigation and Life Sciences Co-Head Elizabeth Weiswasser; Regulatory counsel John O’Loughlin; Technology & IP Transactions associates Lauren Springer and Caleb Small (Not Yet Admitted in New York); Tax associate Eric Remijan; Executive Compensation & Benefits associates Amanda Rosenblum and Travis Bruno (Not Yet Admitted in New York); and Patent Litigation associates Aaron Pereira and Natalie Kennedy.